We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for ipilimumab (Bristol-Myers Squibb Australia Pty Ltd)
Active ingredients
ipilimumab
Date of review outcome
Lapse date
Type
Priority review
Indication
Yervoy in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma
Therapeutic area
Oncology